• LeMaitre filed 2025 annual report covering year ended Dec. 31, 2025, outlining strategy centered on vascular-surgeon call point, niche product segments, direct sales expansion, acquisitions.
• Business mix stayed weighted to open surgery, with over 95% of 2025 net sales tied to devices used in open surgical procedures.
• Biologics remained majority of portfolio, representing 53% of 2025 sales; company ended U.S. distribution agreement for Elutia cardiovascular porcine patches effective May 1, 2025.
• Expansion of allograft tissue services in Europe advanced, with Germany granting approval for import and sale of tissue produced at Fox River Grove facility in October 2025.
• Company flagged January 2026 cybersecurity incident, reporting minimal operational disruption while investigation into potentially impacted data continues.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LeMaitre Vascular Inc. published the original content used to generate this news brief on April 14, 2026, and is solely responsible for the information contained therein.